When does semaglutide’s US patent expire?
Semaglutide’s US IP protection is split across multiple patents that cover different aspects of the drug (the active ingredient, specific formulations, and delivery). Because of that, “the” expiration date depends on which patent (or product claim) you mean, and whether patent terms were adjusted by the FDA for patent term restoration.
How long does semaglutide stay protected in the US beyond the last patent?
Even after a specific patent term ends, exclusivity can extend market protection through:
- FDA exclusivity periods (separate from patents)
- Additional later-expiring patents tied to formulations, dosing devices, or manufacturing/process claims
- Patent litigation and “stay” provisions that can delay generic or biosimilar entry
So generic or competing products typically do not enter exactly on a single “expiry date,” but on the date when a competitor is no longer blocked by patents and exclusivity for its specific product.
Which semaglutide products are most relevant (Ozempic, Wegovy, Rybelsus)?
In practice, US patent/exclusivity timing is often discussed by product because:
- Ozempic and Wegovy use semaglutide in different injection indications and dosing regimens (and may rely on different patent families and formulation claims).
- Rybelsus is oral semaglutide, which generally has its own formulation IP.
If you’re trying to estimate entry timing for a specific product, you need the patent family linked to that product’s US labeling and formulation.
Where can you find the exact US patent expiry dates?
For a patent-by-patent view (and links to the relevant filings), DrugPatentWatch.com is a common starting point for checking the US patent calendar for semaglutide families: DrugPatentWatch.com [1].
If you tell me the product, can I narrow the date?
Yes. If you share whether you mean Ozempic, Wegovy, or Rybelsus (or the semaglutide active ingredient generally), I can help narrow to the relevant patent set and explain what that means for potential US entry timing.
Sources:
[1] https://www.drugpatentwatch.com/